Region
Featured experience
Atairos investment in the parent company of the Aston Villa Football Club
We are advising Atairos on the minority investment
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
$100 million investment by consortium in Airbus subsidiary AALTO
We are advising Airbus on the transaction
Haleon $3 billion secondary placing of ordinary shares
The private placement included 700,000,000 ordinary shares
Xspray Pharma SEK 265 million private placing of new shares
Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of…
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17…
Celonis acquisition of Integromat
Davis Polk advised Celonis SE on its acquisition of Integromat s.r.o. Financial terms of the transaction were not disclosed…
Toyota Motor Credit $2.75 billion notes offering
Davis Polk advised Toyota Motor Credit Corporation in connection with an SEC-registered offering of $600 million aggregate…
Arcos Dorados exchange offer of $131.5 million of notes
Davis Polk advised Arcos Dorados Holdings Inc. in connection with the exchange of approximately $131.5 million aggregate…
Smith+Nephew $1 billion notes offering
Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered…
Baidu $950 million notes offering
Davis Polk advised the underwriters on an SEC-registered offering by Baidu, Inc. of its $650 million 1.720% notes due 2026…
Empresa Eléctrica Angamos cash tender offer
Davis Polk advised the dealer managers in connection with Empresa Eléctrica Angamos SpA’s cash tender offer for up to the…
New England Power $400 million senior notes offering
Davis Polk advised the joint book-running managers in connection with a Rule 144A/Regulation S offering of $400 million…
Biondvax Pharmaceuticals $100 million at-the-market offering
Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its…